Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7YII9)

• Drug Name: Dazodalibep Drug Info
• Synonyms: VIB4920

Indication

Disease Entry	ICD 11	Status	REF
Kidney transplant rejection	NE84	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]
Sjogren syndrome	4A43.20	Phase 2	[3]

• Cross-matching ID: TTD Drug ID: DM7YII9

Molecule-Related Drug Atlas

Drug(s) Targeting CD40L receptor (CD40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[5]
APX005M	DMX2P5G	Melanoma	2C30	Phase 2	[6]
ASKP-1240	DM1CLKO	Transplant rejection	NE84	Phase 2	[7]
CFZ533	DM1TWIE	Graves disease	5A02.0	Phase 2	[5]
Iscalimab	DMW4CR8	Type-1 diabetes	5A10	Phase 2	[8]
KPL-404	DMQJODL	Rheumatoid arthritis	FA20	Phase 2	[9]
AT-1501	DMQIA5K	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[10]
Frexalimab	DMMJTYP	Multiple sclerosis	8A40	Phase 2	[11]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[12]
GEN1042	DMNP6T3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Inhibitor	[4]

References

• [1] ClinicalTrials.gov (NCT04046549) A Phase 2a Single-arm, Prospective, Open-label Pilot Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04163991) A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04129164) A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects With Sj?gren's Syndrome (SS). U.S.National Institutes of Health.
• [4] The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
• [8] Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.
• [9] Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5.
• [10] ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
• [11] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.
• [12] Clinical pipeline report, company report or official report of Shattuck Labs.
• [13] Clinical pipeline report, company report or official report of Genmab.